SME · BSE SMEListed

Goldline Pharmaceutical Limited IPO: dates, price band, lot size, objects of the issue

Get analyst updates on this IPO

Analyst updates come by email.

What changed since listing, from SEBI-registered research analysts.

By continuing you agree to the Terms and Privacy policy

Updated Tue 17 Nov 2026, 10:51 am IST · Source: Prospectus dated Thu 14 May 2026

Bid dates
Tue 12 May 2026 to Thu 14 May 2026
Listing date
Tue 19 May 2026
Issue price
₹43 per share

Listed on BSE on Tue 19 May 2026.

Listing price ₹59.75

Opening price on BSE on the listing day (BSE daily price file for Tue 19 May 2026)

This page is now frozen. Facts stay as filed; the quote is on the exchange.

Key facts

Issue price
₹43 per share
Prospectus dated Thu 14 May 2026, page 2
Lot size
Not stated in the prospectus
Prospectus dated Thu 14 May 2026
Lot amount at the upper band
Not stated in the prospectus
Prospectus dated Thu 14 May 2026
Issue size at the upper band
₹11.61 crore
Fresh issue
₹11.61 crore
Prospectus dated Thu 14 May 2026, page 57
Offer for sale
None
Prospectus dated Thu 14 May 2026, page 1
Bid dates
Tue 12 May 2026 to Thu 14 May 2026
Prospectus dated Thu 14 May 2026, page 71
Listing date
Tue 19 May 2026
BSE daily price file for Tue 19 May 2026
Anchor lock-in ends
Not stated in the prospectus
Prospectus dated Thu 14 May 2026
Risk factors
78
Prospectus dated Thu 14 May 2026, page 56

Timeline (IST)

  1. OpensTue 12 May 2026, 10:00 am IST confirmedProspectus dated Thu 14 May 2026, page 71
  2. ClosesThu 14 May 2026 confirmedProspectus dated Thu 14 May 2026, page 71
  3. UPI mandate cut-offNot stated in the prospectus Prospectus dated Thu 14 May 2026
  4. AllotmentFri 15 May 2026 by T+3 schedule
  5. Refund and unblockMon 18 May 2026 by T+3 schedule
  6. Shares to dematMon 18 May 2026 by T+3 schedule
  7. ListingTue 19 May 2026 confirmedBSE daily price file for Tue 19 May 2026

Objects of the issue

ObjectAmount
Repayment of all or a portion of certain outstanding borrowings availed by our company₹8.35 crore
General corporate purposes₹1.71 crore
Total₹10.06 crore

Prospectus dated Thu 14 May 2026, page 89

Company and promoters

As described in the prospectus

We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”

Prospectus dated Thu 14 May 2026, page 127

Promoters

  • 2 individual promoters

Prospectus dated Thu 14 May 2026, page 196

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group79.70%Not stated in the prospectus
Public20.30%Not stated in the prospectus

Prospectus dated Thu 14 May 2026, page 80

Financials (restated)

ItemNine months ended December 31, 2025March 31, 2025March 31, 2024March 31, 2023
Revenue from operations₹21.41 crore₹28.06 crore₹23.57 crore₹19.85 crore
Profit after tax₹2.22 crore₹2.83 crore₹1.80 crore₹25.66 lakh
Net worth₹12.36 crore₹10.35 crore₹7.86 crore₹5.89 crore
Total borrowingsNot stated in the prospectusNot stated in the prospectusNot stated in the prospectusNot stated in the prospectus

Prospectus dated Thu 14 May 2026, page 60

SME issue facts

Peer comparison (as in the Prospectus)

Name of the CompanyFace value (₹)Revenue from operations (₹ in Lakhs)(1)Basic EPS (₹)Diluted EPS (₹)P/E (based on Diluted EPS)Return on net worth (%)NAV per Equity Share (₹)
Goldline Pharmaceutical Limited102,805.574.104.1010.4927.3712.38
Mono Pharmacare Limited1016,834.491.751.757.579.9017.66
Chandra Bhagat Pharma Limited108,671.611.141.1428.942.8639.72

Reproduced from the Prospectus dated Thu 14 May 2026, page 97; InsightPier adds no figures

Risk factors

78 total
  1. The company depends fully on outside contract manufacturers to make its products (offer document page 20)
  2. The company has filed forms with the Registrar of Companies late in the past and paid late fees (offer document page 23)
  3. The business depends on economic conditions in India (offer document page 55)
  4. Foreign investors face restrictions under Indian law (offer document page 55)
  5. Wars and conflicts abroad may affect the global economy and the business (offer document page 56)

All 78 risk factors, pages 19 to 56

Offer document

Allotment and bids

Registrar to the issue: Bigshare Services Private Limited.

Allotment status was expected on the registrar's site from Fri 15 May 2026 and is not yet confirmed. Pick "Goldline Pharmaceutical Limited" from the issue list there.

Subscription (final)

CategoryShares offeredShares bid forTimes subscribed
Overall––840.74×

ipowatch.in, as of Tue 17 Nov 2026

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts